Nemaura, Sparsha ink drug-delivery deal

Nemaura Pharma said today that it entered into a strategic collaboration with Sparsha Pharma USA for the development and manufacturing of transdermal drug delivery systems.

The terms of the agreement state that Loughborough, England-based Nemaura will develop transdermal therapeutic systems at its facilities in the U.K., up to pilot clinical manufacture, for both global pharmaceutical companies and internally funded programs.

Sparsha Pharma is set to manufacture for Nemaura Pharma’s developments for the U.S., Canadian and Latin American markets. The FDA successfully audited Sparsha’s good manufacturing practice facility, deeming that the Oceanside, Calif.-based company’s facility has the capacity for end-to-end manufacturing of multiple transdermal patches and thin films for the American markets, according to a news release.

Nemaura Pharma said five of its 20 drugs in development are transdermal patches for various global multinationals, and the company has the manufacturing capabilities for patches and injectable drugs.

“We are delighted to enter into this strategic collaboration which brings together our formulation specialism for complex drug delivery systems and Sparsha’s wealth of experience in the manufacture of transdermal therapeutic systems to serve the largest global healthcare market, from their state of the art facility,” Nemaura Pharma CEO Dr. Faz Chowdhury said in prepared remarks.

“There are excellent synergies between Nemaura Pharma and Sparsha USA and this collaboration will allow us to utilize the complementary skills, expertise and resources of the two organizations and allow us to access a greater share of the market,” added Sparsha CEO Dange Veerapaneni.